Bone Biologics Corporation provides an update on the development of NB1, a key orthobiologic product for spine fusion markets.
The company is optimistic about the potential of NB1 to address bone-related indications and improve safety profiles in orthobiologics.
Progress report includes information on the first-in-human study of NB1 and product improvements achieved by Bone Biologics.
First-in-Human Study Progress
Pilot clinical study with NB1 in Australia evaluating safety and effectiveness in patients with degenerative disc disease.
Product Improvements Achieved
Stability studies extending protein shelf life to 18 months and formulation enhancements for future scaled studies.
One-Year Outlook
Plans to add hospital sites, complete enrollment in pilot study, extend shelf life to 24 months, and provide interim trial updates.
Opportunity for NB1
Addressing the need for improved fusion rates and safety in spine fusion procedures with NB1 solution for hard-to-heal bones.
- Bone Biologics anticipates completing enrollment in the pilot study by year-end despite slower-than-expected progress.
- Recent stability studies achieved a significant improvement in protein shelf life and formulation, supporting future manufacturing capabilities.
- The company's one-year outlook includes strategic milestones to enhance value creation and advance the clinical development program for NB1.
Bone Biologics remains committed to advancing NB1 along the clinical and regulatory pathway, emphasizing the potential benefits for spinal fusion patients and stockholders. The company expresses gratitude for ongoing support from all stakeholders.